Compare Newmont Corporation (NEM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs TransMedics Group Inc — how do they compare? Newmont Corporation trades at $117.8 (market cap $121.75B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Newmont Corporation is far larger — about 44.4× TransMedics Group Inc's market cap, and Newmont Corporation pays a 0.9% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and TransMedics Group Inc for 24 Days on average.
| NEM | TMDX | |
|---|---|---|
Market Cap | $121.75B | $2.74B |
Volume | 5,421,125 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $150.42 |
52-Week Low | $78.63 | $61.99 |
Typical Hold Time | 58 Days | 24 Days |
Enterprise Value | $118.34B | $3.13B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont (NEM) trades at $118.23, up 4.13% today, supported by strong earnings beats and record free cash flow. The stock shows a bearish technical signal near key support at $114, while fundamentals are robust with a P/E of 14.57, net income margin of 33.36%, and revenue growth to $22.67B in 2025. Analyst consensus is strongly bullish with a $136.83 price target.
The outlook for NEM is positive, driven by operational improvements and a constructive gold market. Key risks include gold price volatility and execution of growth projects. With no analyst sell ratings and strong institutional interest, the stock presents a compelling opportunity for investors seeking exposure to a leading gold producer.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
